Download PDF
Semin Thromb Hemost 2000; Volume 26(Number 03): 243-254
DOI: 10.1055/s-2000-8469
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Homocysteine, Coagulation, Platelet Function, and Thrombosis

ANTONIO. COPPOLA, GIOVANNI. DAVI, VALENTINO. DE STEFANO, FRANCESCO. P. MANCINI1 , ANNA. MARIA. CERBONE, GIOVANNI. DI MINNO
  • Departments of Clinical and Experimental Medicine, University of Naples ``Federico II,'' Naples, Italy
  • 1Department of Biochemistry and Biomedical Technology, University of Naples ``Federico II,'' Naples, Italy
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

ABSTRACT

Over the last 30 years, a growing body of evidence has documented the role of hyperhomocysteinemia (HHcy) as an independent vascular risk factor. However, the mechanisms through which elevated circulating levels of homocysteine (Hcy) cause vascular injury and promote thrombosis remain elusive. Most findings have been achieved in in vitro studies employing exceedingly high concentrations of Hcy, whereas only a few studies have been carried out in vivo in humans. In homocystinuric patients, homozygotes for mutations of the gene coding for the cystathionine β-synthase enzyme, abnormalities of coagulation variables reflecting a hypercoagulable state, have been reported. In vitro studies provide a biochemical background for such a state. In homocystinuric patients, an in vivo platelet activation has also been reported. The latter abnormality is not corrected by the bolus infusion of concentrations of hirudin, which determines a long-lasting impairment of the conversion of fibrinogen to fibrin by thrombin; in contrast, it appears at least in part lowered by the administration of the antioxidant drug probucol. During the autooxidation of Hcy in plasma, reactive oxygen species are generated. The latter initiate lipid peroxidation in cell membranes (potentially responsible for endothelial dysfunction) and in circulating lipoproteins. Oxidized low-density lipoproteins (LDL) may trigger platelet activation as well as some of the hemostatic abnormalities reported in such patients. Thus the oxidative stress induced by Hcy may be a key process in the pathogenesis of thrombosis in HHcy.

Accumulation of adenosylhomocysteine in cells (a consequence of high circulating levels of homocysteine) inhibits methyltransferase enzymes, in turn preventing repair of aged or damaged cells. This mechanism has been recently documented in patients with renal failure and HHcy and provides an additional direction to be followed to understand the tendency to thrombosis in moderate HHcy.

KEYWORD

Homocysteine - platelets - hypercoagulable state - oxidative stress - endothelial dysfunction

REFERENCES

  • 1 McCully K S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis.  Am J Pathol . 1969;  56 111-128
    Google Scholar
  • 2 Boushey C J, Beresford S AA, Omenn G S, Motulsky A G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease.  JAMA . 1995;  274 1049-1057
    Google Scholar
  • 3 den Heijer M, Rosendaal F R, Blom H J, Gerritz W BJ, Bos G MJ. Hyperhomocysteinemia and venous thrombosis: A meta-analysis.  Thromb Haemost . 1998;  80 874-877
    PubMedGoogle Scholar
  • 4 Mudd S H, Levy H L. Disorders in transsulfuration. in: Scriver C, Beaudet A, Sly W, Valle D, eds. The Metabolic Basis of Inherited Disease New York: McGraw-Hill 1989: 693-734
    Google Scholar
  • 5 Kang S S, Wong P WK. Genetic and non-genetic factors for moderate hyperhomocysteinemia.  Atherosclerosis . 1994;  119 135-138
    PubMedGoogle Scholar
  • 6 Harker L A, Slichter S J, Scott R C, Ross R. Homocysteinemia. Vascular injury and arterial thrombosis.  N Engl J Med . 1974;  291 537-543
    CrossrefPubMedGoogle Scholar
  • 7 Harker L A, Ross R, Slichter S J, Scott C R. Homocysteine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis.  J Clin Invest . 1976;  58 731-741
    PubMedGoogle Scholar
  • 8 Giannini M J, Coleman M, Innerfield I. Antithrombin activity in homocystinuria.  Lancet . 1975;  1 1094
    PubMedGoogle Scholar
  • 9 Maruyama I, Fukuda R, Kazama M. A case of homocystinuria with low antithrombin activity.  Acta Haematol Jpn . 1977;  40 267-271
    PubMedGoogle Scholar
  • 10 Palareti G, Salardi S, Piazzi S. Blood coagulation changes in homocystinuria: Effects of pyroxidine and other specific therapy.  J Pediatr . 1986;  109 1001-1006
    PubMedGoogle Scholar
  • 11 Munnich A, Saudbray J-M, Dautzenberg M-D. Diet-responsive proconvertin (Factor VII) deficiency in homocystinuria.  J Pediatr . 1983;  102 730-734
    PubMedGoogle Scholar
  • 12 Mercky J, Kuntz F. Deficit en facteur VII et homocystinnurie. Association fortuite ou syndrome?.  Nouv Presse Med . 1981;  10 3796
    PubMedGoogle Scholar
  • 13 Charlot J C, Haye C, Chaumien J P. Homocystinurie et deficit en facteur VII.  Bull Soc Ophtalmol Fr . 1982;  82 787-789
    PubMedGoogle Scholar
  • 14 Coppola A, Cerbone A M, Guiotto G. A hypercoagulable state in homocystinuria due to homozygous cystathionine-β-synthase deficiency.  Thromb Haemost . 1997;  528 (528)
    PubMedGoogle Scholar
  • 15 Ratnoff O D. Activation of Hageman factor by L-homocysteine.  Science . 1968;  162 1007-1009
    PubMedGoogle Scholar
  • 16 Fryer R H, Wilson B D, Gubler D B, Fitzgerald L A, Rodgers G M. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells.  Arterioscler Thromb . 1993;  13 1327-1333
    PubMedGoogle Scholar
  • 17 Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells.  J Clin Invest . 1993;  92 1381-1386
    PubMedGoogle Scholar
  • 18 Rodgers G M, Kane W H. Activation of endogenous factor V by homocysteine-induced vascular endothelial cell activator.  J Clin Invest . 1986;  77 1909-1916
    PubMedGoogle Scholar
  • 19 Rodgers G M, Conn M T. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells.  Blood . 1990;  75 895-901
    PubMedGoogle Scholar
  • 20 Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells.  Blood . 1992;  79 2930-2936
    PubMedGoogle Scholar
  • 21 Lentz S R, Sadler J E. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine.  J Clin Invest . 1991;  88 1906-1914
    PubMedGoogle Scholar
  • 22 Hajjar K A. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor.  J Clin Invest . 1993;  91 2873-2879
    CrossrefPubMedGoogle Scholar
  • 23 Harpel P C, Chang V T, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism.  Proc Natl Acad Sci USA . 1992;  89 10193-10197
    PubMedGoogle Scholar
  • 24 Harker L A, Scott R C. Platelets in homocystinuria.  N Engl J Med . 1977;  296 818
    PubMedGoogle Scholar
  • 25 Uhlemann E R, Tenpas J H, Lucky A W. Platelets survival and morphology in homocystinuria due to cystathionine-β-synthase.  N Engl J Med . 1976;  295 1283-1286
    PubMedGoogle Scholar
  • 26 Hill-Zobel R L, Pyeritz R E, Scheffel U. Kinetics and distribution of Indium-labeled platelets in patients with homocystinuria due to cystathionine synthase deficiency.  N Engl J Med . 1982;  307 781-786
    PubMedGoogle Scholar
  • 27 Graeber J E, Slott J H, Ulane R, Schulman J D, Stuart J J. Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism.  Pediatr Res . 1982;  16 490-493
    PubMedGoogle Scholar
  • 28 Roberts L J, Sweetman H BJ, Oates J A. Metabolism of thromboxane B2 in man.  Identification of twenty urinary metabolites. J Biol Chem . 1981;  256 8384-8393
    PubMedGoogle Scholar
  • 29 Patrono C, Davi G, Ciabattoni G. Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors.  Trends Cardiovasc Med . 1992;  2 15-20
    CrossrefPubMedGoogle Scholar
  • 30 Vesterqvist O, Gréen K. Urinary excretion of 2,3-dinor-thromboxane B2 in man under normal conditions, following drugs and during some pathological conditions.  Prostaglandins . 1984;  27 627-644
    CrossrefPubMedGoogle Scholar
  • 31 Di Minno G, Davi G, Margaglione M. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism.  J Clin Invest . 1993;  92 1400-1406
    CrossrefPubMedGoogle Scholar
  • 32 Ciabattoni G, Maclouf J, Catella F, FitzGerald G A, Patrono C. Radioimmunoassay of 11-dehydro-thromboxane B2 in human plasma and urine.  Biochim Biophys Acta . 1987;  918 293-297
    PubMedGoogle Scholar
  • 33 Patrignani P, Filabozzi P, Patrono C. Selective, cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.  J Clin Invest . 1982;  69 1366-1372
    CrossrefPubMedGoogle Scholar
  • 34 Glusa E. Hirudin and platelets.  Semin Thromb Hemost . 1991;  17 122-125
    PubMedGoogle Scholar
  • 35 Markwardt F. The development of hirudin as an antithrombotic drug.  Thromb Res . 1994;  74 1-23
    CrossrefPubMedGoogle Scholar
  • 36 Di Minno G, Coppola A, Cerbone A M. Hirudin does not affect the abnormally high thromboxane biosynthesis in homozygous homocystinuria.  Fibrinolysis . 1996;  36 (36)
    PubMedGoogle Scholar
  • 37 Velury S, Howell S B. Measurement of plasma thiols after derivatization with monobromobimane.  J Chromatogr . 1988;  424 141-146
    PubMedGoogle Scholar
  • 38 Andersson A, Lindgren A, Hultberg B. Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols from plasma of healthy subjects and patients with cerebral infarction.  Clin Chem . 1995;  41 361-366
    PubMedGoogle Scholar
  • 39 Misra H P. Generation of superoxide free radical during the autooxidation of thiols.  J Biol Chem . 1974;  249 2151-2155
    PubMedGoogle Scholar
  • 40 Rowley D A, Halliwell B. Superoxide-dependent formation of hydroxyl radicals in the presence of thiol compounds.  FEBS Lett . 1982;  138 33-36
    CrossrefPubMedGoogle Scholar
  • 41 Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia.  J Clin Invest . 1996;  98 5-7
    CrossrefPubMedGoogle Scholar
  • 42 Heinecke J W, Rosen H, Suzuki L A, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells.  J Biol Chem . 1987;  262 10098-10103
    PubMedGoogle Scholar
  • 43 Ardlie N J, Selley M L, Simons L A. Platelet activation by oxidatively modified low density lipoproteins.  Atherosclerosis . 1989;  76 117-124
    PubMedGoogle Scholar
  • 44 Parthasarathy S, Young S G, Witzum J L, Pittman R C, Steinberg D. Probucol inhibits oxidative modification of low density lipoproteins.  J Clin Invest . 1986;  77 641-644
    CrossrefPubMedGoogle Scholar
  • 45 Starkebaum G, Harlan J M. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine.  J Clin Invest . 1986;  77 1370-1376
    CrossrefPubMedGoogle Scholar
  • 46 Wall R T, Harlan J M, Harker L A, Striker G E. Homocysteine-induced endothelial cell injury in vitro: A model for the study of vascular injury.  Thromb Res . 1980;  18 113-121
    CrossrefPubMedGoogle Scholar
  • 47 Blann A D. Endothelial cell damage and homocysteine.  Atherosclerosis . 1992;  94 89-91
    PubMedGoogle Scholar
  • 48 de Groot P G, Willems C, Boers G HJ. Endothelial cell dysfunction in homocystinuria.  Eur J Clin Invest . 1983;  13 405-410
    CrossrefPubMedGoogle Scholar
  • 49 Stamler J S, Osborne J A, Jaraki M. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen.  J Clin Invest . 1993;  91 308-318
    PubMedGoogle Scholar
  • 50 Liao J K, Shin W S, Lee W Y, Clark S L. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase.  J Biol Chem . 1995;  270 319-324
    CrossrefPubMedGoogle Scholar
  • 51 Chin J H, Azhar S, Hoffman B B. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins.  J Clin Invest . 1992;  89 10-18
    PubMedGoogle Scholar
  • 52 Stamler J S, Simon D I, Osborne J A. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds.  Proc Natl Acad Sci USA . 1992;  89 444-448
    CrossrefPubMedGoogle Scholar
  • 53 Wang J, Dudman N PB, Wilken D E. Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells.  Thromb Haemost . 1993;  6 1047-1052
    PubMedGoogle Scholar
  • 54 Lentz S R, Sobey C G, Piegors D J. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia.  J Clin Invest . 1996;  98 24-29
    PubMedGoogle Scholar
  • 55 Celermajer D S, Sorensen K, Ryalls M. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents.  J Am Coll Cardiol . 1993;  22 854-858
    CrossrefPubMedGoogle Scholar
  • 56 Chambers J C, McGregor A, Jean-Marie J, Obeid O A, Kooner J S. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia.  An effect reversible with vitamin C therapy. Circulation . 1999;  99 1156-1160
    PubMedGoogle Scholar
  • 57 Tsai J-C, Perrella M A, Yoshizumi M. Promotion of vascular smooth muscle cells growth by homocysteine: A link to atherosclerosis.  Proc Natl Acad Sci USA . 1994;  91 6369-6373
    PubMedGoogle Scholar
  • 58 Harker L A, Harlan J M, Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons.  Circ Res . 1983;  53 731-739
    PubMedGoogle Scholar
  • 59 Welch G N, Upchurch Jr G R, Farivar R S. Homocysteine-induced nitric oxide production in vascular smooth cells by NF-κB dependent transcriptional activity of Nos2.  Proc Am Assoc Phys . 1998;  110 22-31
    PubMedGoogle Scholar
  • 60 Bellas R E, Lee J S, Sonenshein G E. Expression of a constitutive NF-kappaB-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells.  J Clin Invest . 1995;  96 2521-2527
    PubMedGoogle Scholar
  • 61 Perna A, Ingrosso D, Zappia V. Enzymatic methyl esterification of membrane proteins is impaired in chronic renal failure.  Evidence for high levels of the natural inhibitor S. adenosylhomocysteine. J Clin Invest . 1993;  91 2497-2503
    PubMedGoogle Scholar
  • 62 Patrono C, FitzGerald G A. Isoprostanes: Potential markers of oxidant stress in atherotrombotic disease.  Arterioscl Thromb Vasc Biol . 1997;  17 2309-2315
    PubMedGoogle Scholar